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Prostate cancer is the second leading cause of cancer death among men in the United States. Despite aggressive hormone therapy (androgen deprivation) along with chemotherapy, patients with metastatic tumors develop resistance to therapies and exhibit clinical and biochemical disease progression. Currently the 5-year survival rate for patients diagnosed with metastatic prostate cancer is ~25% (1) . Because the majority of prostate cancers are likely to remain as indolent tumors, a great challenge to physicians is to identify those tumors with the potential to metastasize so that these patients will have an option for specific treatment (2) .
The androgen receptor (AR) is a key regulator of prostate growth and the principal drug target for the treatment of prostate cancer because, as a nuclear receptor transcription factor, AR controls expression of genes important to prostate cancer cell growth and progression, and the development of castration-resistant prostate cancer (CRPC) (3, 4) . While hormone therapy is the primary treatment for advanced prostate cancer, the development of CRPC after androgen deprivation therapy remains the major challenge in the treatment of advanced prostate cancer (5) . Evidence indicates that continuous AR signaling constitutes a major mechanism of castration-resistant progression (6) . However, it is not fully understood as to how AR signaling is reactivated after castration, leading to castration resistance. This may be attributable to the fact that we still do not have a comprehensive picture of AR-mediated signaling pathway.
Therefore, there is a critical need for a better understanding of AR regulatory network.
Transcriptome analyses have suggested that, although only 1-2% of the mammalian genome is protein-coding, whereas the vast majority of transcripts are non-coding RNAs. Among them are long noncoding RNAs (lncRNAs) with molecular weight of >200 bases in length (7, 8) . Many of the identified lncRNAs show spatial-and temporal-specific patterns of expression. Almost every step in the life cycle of genes can be influenced by lncRNAs. Generally, lncRNAs have been implicated in generegulatory roles, such as chromosome dosage-compensation, imprinting, epigenetic regulation, cell cycle control, nuclear and cytoplasmic trafficking, transcription, translation, splicing, cell differentiation, and others.
Recent progress suggests that the involvement of lncRNAs in human diseases could be far more prevalent than previously appreciated. For example, HOTAIR was shown to reprogram chromatin state to promote breast cancer metastasis by genomewide relocalization of protein repression complex 2 (PRC2), leading to epigenetic silencing of metastasis suppressor genes. Similarly, prostate cancer associate transcript 1 (PCAT-1) is a prostate cancer-specific regulator of cell proliferation and serves as a target of the PRC2 (9) . Other lncRNAs associated with prostate cancer include ANRIL and PCAT-1. For example, ANRIL, also upregulated in prostate cancer, is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15 (10, 11) . Together, these studies suggest that lncRNAs are an important player in prostate cancer biology and some of these lncRNAs could be valuable biomarkers and therapeutic targets in prostate cancer. However, it remains to be determined as to whether lncRNAs can play a role in prostate cancer progression through interaction with AR.
The purpose of this study is to identify long non-coding RNAs (lncRNAs) that play a role in prostate cancer progression so that such lncRNAs may serve as biomarkers to distinguish indolent from aggressive prostate cancer or to predict the therapeutic response.
Body

PCGEM1 is an AR-associated lncRNA in prostate cancer cells
Due to the important role of AR in prostate cancer progression and CRPC, we switched our object from identifying PCR2-associated lncRNAs in prostate cancer cells to identifying lncRNAs that contribute to prostate cancer progression through interaction with AR. Native RNA immunoprecipitations (RIP) previously identified RepA, Xist, and Tsix as PRC2-interacting RNAs (12) . Here, we ulitized a method of capturing the genome-wide pool bound to AR by combining native RIP (12) and RNAseq (13) . Briefly, nuclear RNAs immunoprecipitated by α-AR antibodies were isolated from prostate cancer cells (LNCaP, Du145, and PC3) exhibiting various degrees of aggressiveness and non-transformed RWPE1 cells. cDNAs created using strand-specific adaptors, and those from 200-1,200 nt were purified and subjected to Illumina sequencing and bioinformatics analysis (Fig. 1A) .
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Protein A beads Fig 1. RIP-seq schematic. RNA immunoprecipitation will be performed in prostate cancer cells. Cell nuclei will be isolated and nuclear lysate will be prepared, treated with DNase, and incubated with α-AR antibodies or control IgG. RNA-protein complexes will be immunoprecipitated with protein A agarose beads and RNA will be extracted. cDNAs will be generated by reverse transcription. Resulting cDNAs will be amplified by forward and reverse Illumina primers. PCR products from 200-1200bp will be sequenced. LNCaP extract was used for this experiment. n = 3; **, p < 0.01.
To further verify PCGEM1 and AR interaction, we performed RNA precipitation using synthetic biotin-labeled PCEGM1 RNA as a probe ( Fig. 2A) . It is evident that PCGEM1 can interact with AR (Fig. 2B ). PCEGM1 consists of three exons with 1603 nucleotides in length. Of interest, the 5'-region of PCGEM1 (PCGEM1-A) seemed to interact with AR better than the full-length PCGEM1 (Fig. 2B) , also suggesting that the binding site(s) may reside in this region. probes revealed the same PCGEM1 distribution pattern. These results demonstrate that the PCGEM1 signal as seen in Fig. 3 is specific. Of interest, while AR was predominantly in the nucleus, PCGEM1 was mainly localized to cytoplasm or nucleoli if it was in the nucleus in the absence of androgen (Fig. 3B ). There was a relatively small amount of co-localization of PCGEM1 and AR, especially in "nuclear speckle-like structures" (Fig. 3B) . However, in the presence of androgen, more AR moved into the nucleus and the nuclear AR signal became stronger; at the same time, more PCGEM1 was also detected in the nucleus (Fig. 3C) . Of particular interest, the co-localization signal became much stronger, especially in the nucleoplasm (Fig. 3C ), suggesting that androgen may promote both nuclear localization of AR and PCGEM1, and their interaction. To better evaluate the clinical relevance of PCGEM1, we determined its expression in a series of prostate tumor samples with different Gleason scores by qPCR. We total examined 14 normal prostate samples and 89 prostate tumor samples. We found PCGEM1 was significantly highly expressed in tumor samples (Fig 4) .
Relative PCGEM1 expression level To explore this possibility, we further evaluate the clinical relevance of PCGEM1 in clinical specimens together with AR. Although FISH for paraffin-imbedded specimens is technically challenging because these specimens often carry a high background of autofluorescence, we were able to manage to reduce the background and obtain specific signals for AR and PCGEM1, respectively (Fig. 7) . For example, in the low grade prostate tumor, the distribution patterns of AR and PCGEM1 were similar to what we observed in LNCaP cells in the absence of androgen (Fig. 7 , left panels). While AR was seen mainly in the nucleus, PCGEM1 was predominantly in the cytoplasm. There was little co-localization. However, in the high grade prostate tumor, we observed a relatively strong co-localization signal of PCGEM1 and AR (Fig. 7, right panels) . Since the epitope of the AR antibody used here was derived from the N-terminus (Cell Signaling, Cat#5153), it is expected to also recognize AR variants lacking ligand binding domain (LBD) such as AR3-V7 (14) , in addition to full length AR. Therefore, it would be of interest to determine whether this increase in co-localization is due to upregulation of alternative AR splicing variants which have been shown to be associated with aggressiveness of prostate cancer and castration resistance (15) .
PCGEM1 promotes prostate cancer growth, colony formation and drug resistance
PCGEM1 is expressed as noncoding poly(A) RNA of 1643 nucleotides. MTT assay was used to measure evaluate relative cell survive rate.
PCGEM1 can increase AR-mediated transcription
After revealing the role of PCGEM1 in cell growth and drug resistance, next question we want to address is whether PCEGM1 also impacts AR-regulated gene expression. For this purpose, we suppressed PCGEM1 in LNCaP cells and observed downregulation of PSA and TMPRSS2 by over 60% (Fig. 10) , both of which are direct targets of AR, suggesting that PCGEM1 can increase AR-mediated transcription.
Together, our results suggest that the interaction between AR and PCGEM1 could be important to the AR-regulated gene expression and may have a clinical significance.
However, the molecular mechanism of this interaction between AR and PCGEM1 and subsequent gene activation still needs further investigation. 
Key Research Accomplishments
• We identified that PCGEM1 is an AR-associated lncRNA in prostate cancer.
• PCGEM1 is highly expressed in prostate tumor tissues and its expression is associated with prostate cancer aggressiveness.
• We demonstrated that localization of PCGEM1 and AR in prostate cancer cells changes in the present of Androgen.
• Co-localization signal of PCGEM1 and AR in clinical samples indicate that PCGEM1 may serve as a biomarker to distinguish aggressive from indolent disease.
• Overexpression studies reveal the role of PCGEM1 in promoting prostate cancer cell growth, colony formation as well as drug resistance.
• Suppression of PCGEM1impacts AR-regulated gene expression, suggesting the interaction between PCGEM1 and AR has biological function in prostate cancer cells.
Reportable Outcomes
Not yet.
Conclusion
Large noncoding RNAs (lncRNAs) are robustly transcribed in the genome, however their potential role in prostate cancer is poorly understood. In this study, using RIP approach in combination of RNAseq, we captured lncRNAs from the genome-wide pool bound to androgen receptor in prostate cancer cells. We successfully identified and confirmed that PCGEM1 is an AR-binding partner. To better evaluate the clinical relevance of PCGEM1, we examined its expression in a series of prostate tumor samples with different Gleason scores by quantitative RT-PCR. We found over all PCGEM1 is highly expressed in tumor samples and its expression level actually is associated with cancer aggressiveness. We then further explored the potential of PCGEM1 as aggressive prostate cancer biomarkers by detecting and quantify levels of PCGEM1 in situ on clinical specimen together with AR. We found nuclear colocalization signal of PCGEM1 and AR is correlated with tumor aggressiveness, indicating that PCGEM1 may serve as a biomarker to distinguish aggressive from indolent disease. Finally, overexpression studies revealed that PCGEM1 plays a role in prostate cancer cells growth, colony formation and drug resistance. On the other hand,
